Insilico Initiates Phase III Clinical Trial for Rentosertib, Its AI-Empowered TNIK Inhibitor for Idiopathic Pulmonary Fibrosis

Summary

Insilico has initiated a Phase III clinical trial for Rentosertib, an AI-empowered TNIK inhibitor, for idiopathic pulmonary fibrosis. The advance follows positive Phase IIa clinical results and represents potentially the first-in-class oral TNIK inhibitor in late-stage development.